Sign in

CIK 0001512762

  • Accelerated filer
  • Smaller reporting company

Coherus Oncology, Inc.

Sign in to watch
Ticker
CHRS
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
FY end
Dec 31
Incorporated
DE
Entity type
Operating
EIN
273615821
Phone
+1 650-649-3530
Business address
C/O DENNIS M. LANFEAR, 333 TWIN DOLPHIN DR, SUITE 600, REDWOOD CITY, CA, 94065
Former names
Coherus BioSciences, Inc., BioGenerics, Inc.
  1. 3/A Insider 3/A
  2. 4 Open-market sale Chief Scientific Officer sold 4,250 shares at an average $21.36 ($90,763)
  3. 4 Exercise or conversion Chief Financial Officer acquired 400 shares (option exercise)
  4. 4 Derivatives Options or other derivatives
  5. 4 Derivatives Options or other derivatives
  6. 4 Open-market sale Chief Scientific Officer sold 6,500 shares at an average $15.29 ($99,397)
  7. 4 Exercise or conversion Director acquired 8,124 shares (option exercise)
  8. 4 Open-market sale Chief Scientific Officer sold 2,000 shares at $15.02 ($30,040)
  9. 4 Open-market sale Chief Scientific Officer sold 4,250 shares at an average $21.47 ($91,252)
  10. 4 Exercise or conversion Chief Scientific Officer acquired 16,000 shares (option exercise)
  11. 4 Open-market sale Chief Scientific Officer sold 11,333 shares at an average $29.49 ($334,197)
  12. 4 Open-market sale President and CEO sold 400 shares at $31.75 ($12,700)
  13. 4 Open-market sale Director sold 15,000 shares at an average $27.49 ($412,425)
  14. 4 Open-market sale Chief Scientific Officer sold 18,416 shares at an average $28.71 ($528,689)
  15. 3 Insider Initial Statement of Ownership
  16. 4 Open-market sale Chief Scientific Officer sold 4,250 shares at an average $18.98 ($80,644)
  17. 4 Open-market sale Chief Scientific Officer sold 11,333 shares at an average $27.39 ($310,393)
  18. 4 Insider Changes in Ownership
  19. 3 Insider Initial Statement of Ownership
  20. 4 Open-market sale Director sold 6,373 shares at $33.50 ($213,508)

Page 17 of 20 · 399 filings